1. At a Glance – Sterile Liquids, Not So Sterile Margins
Amanta Healthcare Ltd is currently quoting at ₹109, with a market cap of ₹425 Cr. In the last 3 months, the stock has corrected ~8%, probably reminding investors that pharma is not always paracetamol for portfolios.
Q3 FY26 revenue came in at ₹74.5 Cr, up 9.8% YoY, while PAT stood at ₹4.63 Cr, up 8.18% YoY. Operating margins are holding at 20.6%, which is decent for a small-cap injectable player.
The stock trades at a P/E of 26.6, slightly below the industry median of ~29.8. ROCE is 14.8%, ROE is 13%, and debt-to-equity sits at 0.88.
This is a sterile injectables manufacturer with IPO cash in hand, expansion plans worth ₹100 Cr, and 72% capacity utilization in 9MFY25.
Question is — are we looking at a steady compounding pharma story… or a capital-intensive margin treadmill?
Let’s scrub in and operate.
2. Introduction – From Gujarat to 120 Jurisdictions
Incorporated in 1994, Amanta Healthcare isn’t making tablets you pop after overeating biryani. They manufacture sterile liquid products — mostly injectables.
This is serious stuff. If their product fails, patients don’t write bad reviews. They call lawyers.
The company operates in:
Fluid therapy
Ophthalmics
Respiratory care
Irrigation solutions
Medical devices
They sell domestically under the “SteriPort” brand and export to over 120 jurisdictions across 19 countries.
IPO in September 2025 raised ₹126 Cr, primarily for capex — new manufacturing lines at Kheda, Gujarat.
Now here’s the interesting part:
Revenue growth over 5 years = 8% CAGR Profit growth over 5 years = 21% CAGR
So margins have improved, but sales growth is not exactly racing ahead.
Is this a hidden turnaround? Or just post-pandemic pharma normalization?
Let’s dissect the business model.
3. Business Model – WTF Do They Even Do?
Imagine a hospital ICU. IV drips everywhere. Saline bottles hanging like festival lights. That’s Amanta’s playground.
They manufacture:
Large Volume Parenterals (LVPs) – think saline and fluid therapy bottles
Small Volume Parenterals (SVPs) – injectable medications
Eye lubricants
Irrigation and first aid solutions
Container closure systems
Their technology includes:
Aseptic Blow-Fill-Seal (ABFS)
Injection Stretch Blow Moulding (ISBM)
Translation: They manufacture plastic bottles and fill them with sterile solutions in one seamless process. Efficiency + lower contamination risk.
Capacity = 33.2 Cr units annually Utilization in 9MFY25 = 72%
So they still have room to grow before hitting full capacity.
